ACT Genomics Holdings Company Limited, an Asian DNA sequencing-based cancer solution provider, closed an equity financing of undisclosed amount.
A group of international investors co-led by CLSA Capital Partners participated in the round.
Founded in 2014 and Led by Dr. Hua Chien Chen, CEO, ACTG aims to provide every cancer patient with personalized genomic information-based treatment plans through a Next Generation Sequencing (“NGS”) platform, Asian genome database, professional bioinformatics and biomedical team in Asia, medical report, and integrated services.
Its flagship NGS panel, ACTOnco®+, investigates 440 cancer-related genes by incorporating a signaling pathway design. ACTOnco®+ provides optimal treatment suggestion to clinicians, including targeted therapies, hormonal therapies, chemotherapies, and immunotherapies, for all solid tumor types.
The company intends to use the funds to strengthen its presence and capabilities across the Pan-Asia region.
Currently, ACT Genomics has operations in Taiwan, Hong Kong, Singapore and Japan and has established a joint venture with Canon Medical System Corporation in Japan to operate cancer genomic profiling service and sequencing data analysis covering Japan.